Lv51
900 积分 2025-02-05 加入
Pre-intervention with intravenous immunoglobulin reverses the immunogenic clearance of PEGylated nanomedicines
3小时前
待确认
Achievable but elusive: LLDAS and DORIS remission in clinical trials of belimumab
5天前
已完结
Achievable but elusive: LLDAS and DORIS remission in clinical trials of belimumab
5天前
已完结
Bispecific T cell engager therapy for refractory rheumatoid arthritis
5天前
已完结
BCMA-Targeted T-Cell–Engager Therapy for Autoimmune Disease
5天前
已完结
BCMA-Targeted T-Cell–Engager Therapy for Autoimmune Disease
5天前
已完结
In vivo genome-wide CRISPR screens of human T cells in solid tumours
9天前
已完结
Decade-long persistence of CD19 CAR T cells in B cell lymphomas
9天前
已完结
In vivo engineering of CAR immune cells by nonviral nanoparticles
14天前
已完结
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
27天前
已完结
皖公网安备34019202002308
